



How MSF operational research in a neglected disease (Buruli ulcer) treatment programme can impact international management guidelines

Daniel O'Brien, Genevieve Ehounou, Nathan Ford, Alexandra Calmy, Micaela Serafini, Franck Wanda, Patrick Nkemenang, Vanessa Christinet

► To cite this version:

Daniel O'Brien, Genevieve Ehounou, Nathan Ford, Alexandra Calmy, Micaela Serafini, et al.. How MSF operational research in a neglected disease (Buruli ulcer) treatment programme can impact international management guidelines. OMS conférence sur l'ulcère de Buruli, Mar 2015, Genève, Switzerland. hal-02562245

HAL Id: hal-02562245

<https://hal.science/hal-02562245>

Submitted on 6 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

How MSF operational research in a neglected disease (Buruli ulcer) treatment programme can impact international management guidelines

O'Brien DP^{1,2,3}, Ehounou G⁴, Ford N⁵, Calmy A⁶, Serafini M⁷, Wanda F⁴, Nkemenang P⁴, Christinet V⁶



1. Manson Unit, Médecins Sans Frontières, London, United Kingdom 2. Department of Infectious Diseases, Barwon Health, Geelong, Australia 3. Department of Medicine and Infectious Diseases, Royal Melbourne Hospital, University of Melbourne, Australia 4. Médecins Sans Frontières, Akonolinga, Cameroon 5. HIV Department, World Health Organisation, Geneva, Switzerland 6. Department of HIV, University Hospitals of Geneva, Geneva, Switzerland 7. Médecins Sans Frontières, Geneva, Switzerland

Introduction

The main burden of Buruli Ulcer (BU) is in West and Central Africa (Figure 1). However this also corresponds to regions with high HIV prevalence (Figure 1), and all 15 countries in West and Central Africa reporting BU cases have an HIV prevalence of 1-5%. Therefore there is a significant potential for BU and HIV to occur in the same individual and BU-HIV coinfection is an important emerging management challenge for BU disease.

Despite this, there is little known about the interaction between BU and HIV. For example, is the prevalence of HIV increased in BU patients? Are there any clinical consequences of HIV infection in BU patients such as effects on disease presentation and severity. Does HIV effect outcomes on treatment such as mortality, time to healing, and cure rates? What are the management implications of HIV infection in BU patients such as when to start antiretroviral therapy and what are the optimum BU treatment regimens to use?

Limited by the paucity of scientific studies, guidance for management of this coinfection has been lacking. Therefore as a WHO initiative, a panel of experts in BU and HIV management were convened to develop guidance principles for the management of BU/HIV coinfection.

Here we describe how analysis of data from the BU treatment programme of Médecins Sans Frontières in Akonolinga, Cameroon provided some of the scientific basis for development of guidance principles for BU/HIV coinfection.



Figure 1. Global distribution of HIV and BU estimated prevalence.

MSF-Akonolinga, Cameroon

- This was a BU treatment programme based in a District Ministry of Health Hospital.
- Prospective data was collected on all BU treated patients.
- The analysis included 1130 patients with a first episode of BU treated from 1/1/2002 to 27/3/2013



Figure 2. On the left an image demonstrating the increased severity of BU disease in HIV coinfecting patients. On the right the BU pavilion in Akonolinga, Cameroon.

Results:

The prevalence of HIV in BU patients

	Female with BU ≥15yrs	Female regional (15-49yrs)	Men with BU ≥15yrs	Men regional (15-49yrs)	Children with BU <15yrs	Children regional	P-value
All BU patients	37% (52/141)	8%	20% (24/123)	4.7%	4% (5/114)	0.68%	<0.001
PCR confirmed BU patients	39% (34/87)	8%	17% (15/88)	4.7%	5% (4/73)	0.68%	<0.001

Figure 3: HIV prevalence in BU patients compared with mean HIV prevalence of local province (2004-2011) for adults and National HIV prevalence among 0-14yrs (UNICEF).

The effect of HIV on the clinical presentation.

	Single lesions	Multiple lesions	p-value
HIV + (n=83)	63 (76%)	20 (24%)	<0.01
HIV - (n=376)	333 (88%)	41 (11%)	

- HIV+ patients tended to have larger BU lesions: diameter 5.5 (IQR 3-12) vs 5.0 cm (IQR 2-9.5; $p=0.12$)
- A higher proportion of HIV+ patients had ulcerated lesions (93% vs 86%; $p=0.12$)

The effect of immunosuppression on the size of a BU lesion

	Cat 1	Cat 2/3	p-value
CD4<500	21 (55%)	40 (80%)	0.02
CD4>500	17 (45%)	10 (20%)	

The level of immune suppression at diagnosis of BU/HIV patients

- 92/121 (76%) HIV+ patients tested since 2002 had CD4 data
- 20 (22%): ≤ 200 cells/mm³
- 44 (48%): 201-500 cells/mm³
- 28 (30%): > 500 cells/mm³

The affect of HIV on mortality

- Mortality rate higher among HIV+ than HIV- BU patients [8/83 (11%) vs 5/376 (1%); $p<0.001$]
- Median CD4 cell count among the eight deceased HIV patients: 229 cells/mm³ (IQR 98-378)
- Median duration until death: 41.5 days (IQR 16.5-56.5 days)
- None were on antiretroviral therapy

The effect of HIV immune suppression on time for BU wound healing



CD4<500 RR: 2.38, 95%CI 1.43-3.96; $p<0.001$

Recommendations of BU/HIV expert panel influenced by results from Akonolinga

- All BU patients should be offered quality provider-initiated HIV testing and counselling
- Combination antibiotic treatment for BU should be commenced before starting ART
- ART should be initiated in all BU/HIV coinfecting patients with symptomatic HIV disease (WHO clinical stage 3 or 4) regardless of CD4 cell count and in those asymptomatic individuals with CD4 count ≤ 500 cells/mm³
- If CD4 count is not available, those in WHO category 2 or 3 BU disease should be offered ART.
- Patients with CD4 ≥ 500 cells/mm³ do not commence ART until CD4 has fallen below 500 cells/mm³ or other criteria for ART have been met
- For eligible individuals, ART should be commenced as soon as possible after the start of BU treatment, preferably within 8 weeks, and as a priority in those with advanced HIV disease (CD4 < 350 cells/mm³ or WHO stage 3 or 4 disease).

Conclusions

An MSF programme focussed on the neglected tropical disease of BU, through clinical practice and study of observational data, allowed acquisition of important knowledge regarding the clinical and epidemiological interactions between BU and HIV disease. This was important in building simple 'common sense' preliminary international guidance for the management of BU/HIV coinfection

Acknowledgements

- MSF/MoH staff and patients Akonolinga, Cameroon
- MSF, Geneva: A. Antierens, L. Rossel, G. Alcoba
- Departments of NTD and HIV WHO: K. Asiedu, M. Vitoria.